MEIRAGTX HOLDINGS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.8 USD | +1.91% |
|
-5.70% | -31.62% |
| Sales 2024 * | 55.77M 4.46B | Sales 2025 * | 273M 21.85B | Capitalization | 309M 24.71B |
|---|---|---|---|---|---|
| Net income 2024 * | -126M -10.09B | Net income 2025 * | 133M 10.65B | EV / Sales 2024 * | 5.54 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.13 x |
| P/E ratio 2024 * |
-2.72
x | P/E ratio 2025 * |
3.61
x | Employees | 422 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on MeiraGTx Holdings plc
More recommendations
More press releases
| 1 day | +1.91% | ||
| 1 week | -5.70% | ||
| Current month | -20.92% | ||
| 1 month | -22.71% | ||
| 3 months | -28.89% | ||
| 6 months | +29.73% | ||
| Current year | -31.62% |
1 week
4.68
5.17
1 month
4.686.22
Current year
4.687.57
1 year
3.498.35
3 years
3.4924.89
5 years
3.4930.23
10 years
3.4930.23
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Giroux
FOU | Founder | 61 | 19/03/15 |
| Chief Executive Officer | 59 | 19/03/15 | |
Robert Zeldin
CTO | Chief Tech/Sci/R&D Officer | 61 | 04/08/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Debra Yu
BRD | Director/Board Member | 59 | 24/04/22 |
Thomas Shenk
BRD | Director/Board Member | 77 | 31/05/15 |
Keith Harris
CHM | Chairman | 71 | 31/05/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +6.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 4.8 | +1.91% | 74,544 |
| 25/04/24 | 4.71 | -3.09% | 121,779 |
| 24/04/24 | 4.86 | -1.42% | 109,845 |
| 23/04/24 | 4.93 | -1.79% | 164,022 |
| 22/04/24 | 5.02 | -1.38% | 154,442 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogrenâs Syndrome; AAV-GAD for the treatment of Parkinsonâs Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.8
USD
Average target price
21.6
USD
Spread / Average Target
+350.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.62% | 309M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MGTX Stock
